Manipal Health IPO 2026 — Date, Price Band, GMP & Review
Manipal Health Enterprises Limited, India's largest hospital chain by bed count, has filed its Draft Red Herring Prospectus (DRHP) with SEBI for what is expected to be one of the largest healthcare IPOs in Indian capital market history. The issue is sized at approximately ₹8,000 crore, with an implied valuation in the range of ₹30,000–₹40,000 crore.
Backed by Temasek (Singapore sovereign wealth fund) via TPG, and with a national footprint of 33 hospitals and 9,500+ operational beds, this IPO is being closely watched by domestic mutual funds and global healthcare investors.
Manipal Health IPO — Key Details at a Glance
| Detail | Information |
|---|---|
| Company | Manipal Health Enterprises Limited |
| IPO Type | Book Build Issue |
| Total Issue Size | ~₹8,000 crore (estimated) |
| Implied Valuation | ₹30,000–40,000 crore |
| Fresh Issue + OFS | Mix to be confirmed |
| Price Band | To be announced |
| Lot Size | To be announced |
| Listing Exchange | BSE and NSE |
| IPO Open Date | To be announced |
| IPO Close Date | To be announced |
| Lead Managers | Kotak Mahindra Capital, Morgan Stanley, JP Morgan, ICICI Securities (expected) |
| Status | DRHP Filed |
Price band, lot size and IPO dates will be announced after SEBI observations. Bookmark this page — we update it live.
What Is Manipal Health Enterprises?
Manipal Health Enterprises is the operating entity behind Manipal Hospitals, founded in 1953 in Bengaluru by Dr T.M.A. Pai. Today the chain is the largest hospital network in India by total bed count, having scaled aggressively through both organic build-out and large M&A — most notably the acquisitions of Columbia Asia Hospitals (2021), Vikram Hospital (2020), and AMRI Hospitals Kolkata (2023).
The company operates 33 hospitals across 17 cities, with 9,500+ beds, 5,000+ doctors, and over 20,000 employees. Its hospitals span tertiary and quaternary care, cardiac sciences, oncology, neurosciences, transplants, and women & child health.
Ownership structure post-acquisitions:
- Temasek (TPG-routed) — ~59% stake
- Manipal Group / Pai Family — ~30%
- Other investors — ~11%
Manipal Health — Hospital Network
| Region | Hospitals | Approximate Beds |
|---|---|---|
| Bengaluru | 9 | 2,800+ |
| Delhi NCR | 4 | 1,400+ |
| Kolkata | 3 (incl. AMRI) | 1,200+ |
| Mumbai | 2 | 700+ |
| Other Tier-1 / Tier-2 | 15 | 3,400+ |
The network is concentrated in metro and Tier-1 cities, where insurance penetration and average revenue per occupied bed (ARPOB) are highest.
Manipal Health — Financial Performance
| Metric | FY23 | FY24 | FY25 |
|---|---|---|---|
| Revenue (₹ Cr) | 4,260 | 5,650 | 7,150 |
| EBITDA (₹ Cr) | 1,030 | 1,360 | 1,790 |
| EBITDA Margin | 24.2% | 24.1% | 25.0% |
| PAT (₹ Cr) | 280 | 470 | 720 |
| ARPOB (₹/day) | 53,000 | 58,000 | 62,500 |
| Occupancy | 64% | 67% | 69% |
Key takeaways:
- Revenue grew at ~30% CAGR between FY23 and FY25, well above the listed peer average of ~17%
- EBITDA margins held above 24% even through a heavy integration phase post-AMRI acquisition
- ARPOB at ₹62,500 is in line with Apollo and ahead of Max Healthcare
- Occupancy improving steadily — implies further operating leverage if it crosses 72%
IPO Objective — Where Will the Money Go?
Per the DRHP, fresh issue proceeds are expected to fund:
- Debt repayment — Manipal carried ~₹3,200 crore of net debt as of FY25 post-AMRI deal
- Greenfield expansion — new hospitals planned in Hyderabad, Chennai, and Pune
- Brownfield bed addition — capacity expansion at existing high-occupancy units
- General corporate purposes
The OFS portion (size yet to be confirmed) provides a partial exit for Temasek/TPG and other early backers.
Manipal Health — Strengths
Largest hospital chain in India: 9,500+ beds gives Manipal greater scale than Apollo Hospitals (~10,000 beds across all formats but more dispersed), Max Healthcare (~3,500 beds), and Fortis (~4,500 beds).
Asset-light management model: A meaningful portion of the network operates under long-term O&M contracts where the real estate is owned by separate entities. This boosts return on capital employed (ROCE).
Strong brand equity: "Manipal" is a trusted clinical brand with 70+ years of heritage, particularly strong in South India.
Tier-1 metro concentration: Hospitals in Bengaluru, Delhi NCR, Mumbai, and Kolkata — the highest-revenue catchments in India — drive premium ARPOB.
Marquee backing: Temasek has held its position through multiple cycles, signalling long-term conviction.
Healthcare tailwinds: India's hospital sector is structurally undersupplied — 1.4 beds per 1,000 people vs 3.0+ in OECD countries.
Manipal Health — Risks to Consider
Regulatory overhang: Hospital pricing is increasingly under government scrutiny — price caps on consumables, stents, and knee implants have already been implemented. Future caps could compress margins.
Private equity overhang: With Temasek/TPG holding ~59%, the OFS structure and any future block sales could create persistent stock supply for several quarters post listing.
Integration risk: Three large acquisitions in the last five years (Columbia Asia, Vikram, AMRI) bring integration risk — culture alignment, IT systems, and clinical protocol standardisation are non-trivial.
Doctor attrition: Senior consultants drive a meaningful portion of revenue. Departures to competitors or independent practices can hit ARPOB.
Insurance dependency: TPA/insurance receivables can stretch working capital. Slow settlement cycles affect cash flow.
Valuation: At an estimated ₹30,000–40,000 crore market cap, Manipal would trade at ~40–55x FY25 P/E. Apollo Hospitals trades at ~70x and Max Healthcare at ~75x — so Manipal could come at a relative discount, but absolute valuations remain rich.
Manipal Health IPO GMP (Grey Market Premium)
GMP data will be updated here once IPO dates are officially announced and grey market trading begins. Bookmark this page or check our live GMP tracker.
Manipal Health IPO — Should You Apply?
Manipal Health represents the largest pure-play listed hospital chain opportunity in India once it lists. The combination of scale, brand, and structural healthcare tailwinds is compelling.
The decision will hinge on price band. If the IPO is priced at a meaningful discount to listed peers (Apollo at ~70x, Max at ~75x), there is room for both listing gains and medium-term compounding. If the price band lands at parity with peers, expect muted listing performance.
Who should consider applying:
- Long-horizon investors seeking healthcare sector exposure
- Investors who believe in India's hospital underpenetration thesis
- Those building a balanced portfolio across Apollo, Max, and Manipal
Who should be cautious:
- Investors uncomfortable with regulatory pricing risk
- Short-term traders — large IPOs often see slow post-listing price discovery
- Anyone allergic to PE-heavy ownership structures
This is not investment advice. Read the Red Herring Prospectus carefully before applying.
How to Apply for Manipal Health IPO
Once dates are announced, you can apply through:
- UPI-based application via Zerodha, Groww, Upstox, Paytm Money, Angel One
- ASBA via your bank's net banking
- Physical forms at designated branches
Use our IPO Allotment Checker to track allotment after the basis is finalised.
Frequently Asked Questions
When will Manipal Health IPO open? The IPO open date has not been announced yet. The DRHP has been filed with SEBI. Dates will be announced after SEBI observations and final RHP. We will update this page as soon as dates are confirmed.
What is Manipal Health IPO size? The IPO is expected to be approximately ₹8,000 crore, comprising a mix of fresh issue and offer for sale (OFS).
Who are the promoters of Manipal Health? The Pai family (Manipal Group founders) along with TPG / Temasek as the largest institutional shareholder.
How many hospitals does Manipal operate? 33 hospitals across 17 cities with 9,500+ operational beds — making it the largest hospital chain in India by bed count.
Is Manipal Health profitable? Yes. Manipal reported PAT of ₹720 crore in FY25, up from ₹470 crore in FY24 and ₹280 crore in FY23.
How does Manipal compare to Apollo and Max Healthcare? Manipal has more beds than either Apollo or Max but slightly lower ARPOB and EBITDA margin than Max Healthcare, which is the most premium of the three. Apollo has more diverse revenue streams (pharmacy, diagnostics, digital).
Last updated: 8 May 2026. This article will be updated as IPO dates, price band, GMP, and allotment details are announced.